Calls
2
Krishna Veeraraghavan
Global Co-Head of M&A, Paul Weiss
Win Rate
100.0%
return
+16.4%
Loading charts...
Ticker
Side
Mentions
First Call
Call Price
P&L
Thesis
Theme
Source
Long
Mar 11
$126.61
+21.8%
You have the large pharmaceutical companies which have these patent cliffs coming off. They're going to lose exclusivity and they need to fill that pipeline... they have an exceeding amount of financial ability and capital to do that. Big Pharma is facing an existential revenue threat as blockbuster drugs lose patent protection. Armed with massive cash reserves, they will be forced to aggressively acquire small and mid-cap biotech companies—specifically in oncology, immunology, and cardiometabolic spaces—to buy innovation, driving up valuations across the entire biotech sector. LONG. A target-rich environment combined with desperate, cash-rich buyers will create significant buyout premiums for innovative biotech firms. Increased FTC antitrust scrutiny could chill mega-mergers, or high-profile clinical trial failures could reduce the pool of viable acquisition targets.
You have the large pharmaceutical companies which have these patent cliffs coming off. They're going to lose exclusivity and they need to fill that pipeline... they have an exceeding amount of financial ability and capital to do that. Big Pharma is facing an existential revenue threat as blockbuster drugs lose patent protection. Armed with massive cash reserves, they will be forced to aggressively acquire small and mid-cap biotech companies—specifically in oncology, immunology, and cardiometabolic spaces—to buy innovation, driving up valuations across the entire biotech sector. LONG. A target-rich environment combined with desperate, cash-rich buyers will create significant buyout premiums for innovative biotech firms. Increased FTC antitrust scrutiny could chill mega-mergers, or high-profile clinical trial failures could reduce the pool of viable acquisition targets.
Thematic ETFs
Long
Mar 11
$170.95
+11.0%
You have the large pharmaceutical companies which have these patent cliffs coming off. They're going to lose exclusivity and they need to fill that pipeline... they have an exceeding amount of financial ability and capital to do that. Big Pharma is facing an existential revenue threat as blockbuster drugs lose patent protection. Armed with massive cash reserves, they will be forced to aggressively acquire small and mid-cap biotech companies—specifically in oncology, immunology, and cardiometabolic spaces—to buy innovation, driving up valuations across the entire biotech sector. LONG. A target-rich environment combined with desperate, cash-rich buyers will create significant buyout premiums for innovative biotech firms. Increased FTC antitrust scrutiny could chill mega-mergers, or high-profile clinical trial failures could reduce the pool of viable acquisition targets.
You have the large pharmaceutical companies which have these patent cliffs coming off. They're going to lose exclusivity and they need to fill that pipeline... they have an exceeding amount of financial ability and capital to do that. Big Pharma is facing an existential revenue threat as blockbuster drugs lose patent protection. Armed with massive cash reserves, they will be forced to aggressively acquire small and mid-cap biotech companies—specifically in oncology, immunology, and cardiometabolic spaces—to buy innovation, driving up valuations across the entire biotech sector. LONG. A target-rich environment combined with desperate, cash-rich buyers will create significant buyout premiums for innovative biotech firms. Increased FTC antitrust scrutiny could chill mega-mergers, or high-profile clinical trial failures could reduce the pool of viable acquisition targets.
Thematic ETFs
Showing 2 of 2 calls · sorted by mentions
Choose a mentions count to open ticker posts.
Krishna Veeraraghavan has 2 trade ideas tracked on Buzzberg across 2 tickers since March 2026. Most covered: XBI, IBB.
